<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818959</url>
  </required_header>
  <id_info>
    <org_study_id>JV04FIM</org_study_id>
    <nct_id>NCT02818959</nct_id>
  </id_info>
  <brief_title>First in Man Study of the JenaValve TAVI Plus System Transfemoral</brief_title>
  <acronym>CP-0001</acronym>
  <official_title>First in Man Study of the JenaValve TAVI Plus System Transfemoral</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JenaValve Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JenaValve Technology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate feasibility, safety and effectiveness of the first&#xD;
      generation transfemoral JenaValve Pericardial TAVR System (formerly named JenaValve TAVI Plus&#xD;
      System- Transfemoral) in an elderly patient population with severe aortic stenosis who are at&#xD;
      high risk for surgical aortic valve replacement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a prospective, multi-center trial conducted at 2 centers in Germany&#xD;
      enrolling up to 12 subjects. Each patient will be followed for 2 years. The last patient's&#xD;
      follow-up will end in February 2016. It is planned that the study will end in June 2016.&#xD;
      Study endpoints are defined in accordance with the &quot;Standardized endpoint definitions for&#xD;
      transcatheter aortic valve implantation clinical trials: a consensus report from the Valve&#xD;
      Academic Research Consortium (VARC-2)&quot;. These endpoint definitions combine the expertise of&#xD;
      surgeons, interventionalists, medical cardiologists, clinical trial and other specialists and&#xD;
      allow for comparison of different trials concerning effectiveness and safety in TAVI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to inability to recruit sufficient sample size in reasonable time frame.&#xD;
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>30-day mortality of procedure is defined as all deaths within 30 days after implantation of the JenaValve Plus Prosthesis irrespective of the underlying cause of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate and standard deviation of VARC-2 Individual Safety Endpoints</measure>
    <time_frame>Index Procedure and Immediate Post-operative</time_frame>
    <description>Myocardial Infarction&#xD;
Stroke&#xD;
Major Bleeding&#xD;
Acute Kidney Injury&#xD;
Vascular Complications&#xD;
Conduction Disturbances and Arrhythmias&#xD;
TAVR-related Complications</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Device Success</measure>
    <time_frame>Index Procedure and Immediate Post-operative</time_frame>
    <description>Absence of procedural mortality AND Correct positioning of a single prosthetic heart valve into the proper anatomical location AND Intended performance of the prosthetic heart valve</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Outcomes through 2-year follow-up - Hemodynamic Performance</measure>
    <time_frame>Prior to discharge, at 3, 6, 12 and 24 months</time_frame>
    <description>Improvement in mean gradient and effective orifice area compared to baseline and over time as assessed by Echocardiogram</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Outcomes through 2-year follow-up - NYHA Functional Classification</measure>
    <time_frame>Prior to discharge, at 3, 6, 12 and 24 months</time_frame>
    <description>Number of patients with improvement over time as compared to baseline</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Transcatheter Aortic Valve Replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended for use in subjects with severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using a delivery system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JenaValve Pericardial TAVR System</intervention_name>
    <description>The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.</description>
    <arm_group_label>Transcatheter Aortic Valve Replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with severe native aortic valve stenosis&#xD;
&#xD;
          -  NYHA functional class II or higher&#xD;
&#xD;
          -  Increased risk for surgical aortic valve replacement&#xD;
&#xD;
          -  Comply with post-operative follow-up visits and requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined aortic valve disease with severe aortic insufficiency&#xD;
&#xD;
          -  Presence of moderate mitral insufficiency or previous mitral prosthesis&#xD;
&#xD;
          -  Severe pulmonary hypertension&#xD;
&#xD;
          -  Congenital uni- or bicuspid aortic valve&#xD;
&#xD;
          -  Endocarditis or active infection&#xD;
&#xD;
          -  Life expectancy &lt; 12 months&#xD;
&#xD;
          -  Need for emergency surgery for any reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Baldus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Koln Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hendrik Treede, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hamburg Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Hamburg Medical Center</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Koln Medical Center</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Disease</keyword>
  <keyword>Aortic Valve Replacement</keyword>
  <keyword>Transcatheter</keyword>
  <keyword>Transfemoral</keyword>
  <keyword>Aortic Stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

